NeuroHagana Ltd
NeuroHagana is pioneering a first-in-class emergency treatment for neurotrauma that interrupts the biological processes leading to irreversible secondary injury. By targeting spinal cord injury, traumatic brain injury and concussion our platform addresses an urgent unmet medical need impacting over 60 million individuals annually in world.
Industries
Nr. of Employees
small (1-50)
NeuroHagana Ltd is currently seeking investment
NeuroHagana Ltd is seeking a seed investment in the range of 1m-5m
Products
Emergency neuroprotective injectable treatment
Simple intravenous injection based on biological enzymes aims to prevent the progression of the damage shortly after the injury. The treatment is designed to be administered by first responders in the field, with continued treatment in hospital.
Emergency neuroprotective injectable treatment
Simple intravenous injection based on biological enzymes aims to prevent the progression of the damage shortly after the injury. The treatment is designed to be administered by first responders in the field, with continued treatment in hospital.
Expertise Areas
- Neuroprotection
- Spinal cord injury treatment
- Acute neurotrauma intervention
- Glutamate toxicity mitigation
Key Technologies
- Blood glutamate scavenging
- Immediate injectable therapeutics
- Animal models for CNS injury
- Magnetic resonance spectroscopy for brain metabolite analysis
Key People
News & Updates
Coverage of the development and demonstration of a therapeutic treatment potentially reducing nerve cell damage and improving mobility after spinal cord injury.
Study correlating increased glutamate levels with poorer neurological outcomes in stroke patients.
Feature on innovative treatments for spinal cord injury, including blood glutamate scavenging.
Analysis of the association between liver enzyme levels and stroke risk.
Study proposing a combination therapy targeting neuroprotection in ALS using GOT1 and oxaloacetic acid.
Use of MRS techniques to demonstrate neuroprotection via glutamate scavenging in the context of nerve agent exposure.
Coverage of the development and demonstration of a therapeutic treatment potentially reducing nerve cell damage and improving mobility after spinal cord injury.
Study correlating increased glutamate levels with poorer neurological outcomes in stroke patients.
Feature on innovative treatments for spinal cord injury, including blood glutamate scavenging.
Analysis of the association between liver enzyme levels and stroke risk.
Study proposing a combination therapy targeting neuroprotection in ALS using GOT1 and oxaloacetic acid.
Use of MRS techniques to demonstrate neuroprotection via glutamate scavenging in the context of nerve agent exposure.